Teva于2025年11月19日推出Teva Raise, 这是一个全球平台,邀请创新者利用AI和数字技术应对药物发展挑战。 Teva launched Teva Rise on Nov. 19, 2025, a global platform inviting innovators to tackle drug development challenges using AI and digital tech.

2025年11月19日推出全球创新平台Teva Rise(Teva Reise), 邀请创业和技术公司利用AI、数字健康、智能制造业等手段, 解决药物开发、制造和供应链方面的七项关键挑战。 Teva Pharmaceutical has launched Teva Rise, a global innovation platform unveiled on November 19, 2025, inviting startups and tech firms to solve seven key challenges in drug development, manufacturing, and supply chain using AI, digital health, and smart manufacturing. 该倡议是Teva增长枢纽战略的一部分,为全球业务提供了试点机会,旨在加速生物实验、临床试验模拟、病人经验和供应链复原力方面的进展。 The initiative, part of Teva’s Pivot to Growth strategy, offers pilot opportunities across its global operations and aims to accelerate advancements in biologics testing, clinical trial simulation, patient experience, and supply chain resilience. 这一举动反映了更广泛的行业趋势,因为Eli Lilly和Johnson & Johnson等大型制药公司与Nvidia和亚马逊网络服务等人工智能领导者深化合作,为药物发现和临床护理构建专门工具,利用生成人工智能和高性能计算来缩短时间表并改善结果. This move reflects a broader industry trend as major pharmaceutical companies like Eli Lilly and Johnson & Johnson deepen partnerships with AI leaders such as Nvidia and Amazon Web Services to build specialized tools for drug discovery and clinical care, leveraging generative AI and high-performance computing to reduce timelines and improve outcomes.